title: Eicosapentaenoic acid inhibits the release of 14C-prostacyclin from a perfused tissue after incorporation of 14C-prostaglandin precursors.
abstract: The isolated rabbit ear was labeled by perfusion either with 14C-arachidonic acid (AA) or 14C-dihomo-gamma-linolenic acid (DGLA). The influence of unlabeled eicosapentaenoic acid (EPA) on the release and metabolism of the labeled prostaglandin (PG) precursors was studied with the aid of radio-thin-layer-chromatography (TLC). After incorporation of 14C-AA, the ionophore A 23187 (10 micrograms) stimulated the release of products comigrating on TLC plates with authentic PGI2 (measured as 6-keto-PGF1 alpha), PGE2, PGD2 and AA. In unlabeled ears, A 23187 (10 micrograms) stimulated the release of PGI2 and PGE2 (determined by radioimmunoassay) in similarly relative amounts as found for the labeled products. The release of PGD2 was not measured. After incorporation of 14C-DGLA, A 23187 (10 micrograms) stimulated the release of labeled products comigrating in several TLC-systems with 6-keto-PGF1 alpha (but not PGF1 alpha), PGE1, PGD1 and DGLA. After incorporation of 14C-AA, infusion of unlabeled EPA (0.1, 1 and 10 micrograms/ml) reduced the release of 14C-PGI2 but not of the other bisenoic PGs. Furthermore, in ears labeled with 14C-DGLA, EPA strongly reduced the release of a product comigrating with 6-keto-PGF1 alpha and to a lesser extent of a product comigrating with PGE1. Infusion of unlabeled EPA (1 and 10 micrograms/ml) did not reduce the release of 14C-AA or 14C-DGLA indicating that a phospholipase A2 was probably not inhibited by EPA. It is concluded that EPA inhibits PGI2 synthase rather than cyclooxygenase since after incorporation of 14C-AA, only the release of PGI2 is reduced.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.forename: H
authors.initials: H
authors.lastname: Juan
authors.forename: W
authors.initials: W
authors.lastname: Sametz
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000096:biosynthesis; D015126:8,11,14-Eicosatrienoic Acid / Q000378:metabolism*; D000527:Alprostadil; D000818:Animals; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000378:metabolism*; D000001:Calcimycin / Q000494:pharmacology; D002855:Chromatography, Thin Layer; D015118:Eicosapentaenoic Acid; D011464:Epoprostenol / Q000378:metabolism*; D005231:Fatty Acids, Unsaturated / Q000378:metabolism* / Q000494:pharmacology*; D011453:Prostaglandins / Q000096:biosynthesis*; D011457:Prostaglandins D / Q000096:biosynthesis; D011458:Prostaglandins E / Q000096:biosynthesis; D011817:Rabbits; D011863:Radioimmunoassay
chemical_list: D001095:Arachidonic Acids; D005231:Fatty Acids, Unsaturated; D011453:Prostaglandins; D011457:Prostaglandins D; D011458:Prostaglandins E; D016718:Arachidonic Acid; D000001:Calcimycin; D015121:6-Ketoprostaglandin F1 alpha; D015118:Eicosapentaenoic Acid; D011464:Epoprostenol; D000527:Alprostadil; D015126:8,11,14-Eicosatrienoic Acid